{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:41:23Z","timestamp":1790138483185,"version":"4.0.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.bneo.2024.100054","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T07:08:02Z","timestamp":1730531282000},"page":"100054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3940-4451","authenticated-orcid":false,"given":"Max J.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milos D.","family":"Miljkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonita","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3123-6844","authenticated-orcid":false,"given":"Rahul","family":"Lakhotia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9661-4570","authenticated-orcid":false,"given":"Christopher","family":"Melani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7688-1439","authenticated-orcid":false,"given":"Stefania","family":"Pittaluga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Waldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis M.","family":"Staudt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wyndham H.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0278-2635","authenticated-orcid":false,"given":"Mark","family":"Roschewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.bneo.2024.100054_bib1","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1002\/j.1460-2075.1995.tb00035.x","article-title":"Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor","volume":"14","author":"Giri","year":"1995","journal-title":"EMBO J"},{"issue":"8","key":"10.1016\/j.bneo.2024.100054_bib2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nri1901","article-title":"The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design","volume":"6","author":"Waldmann","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.bneo.2024.100054_bib3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.bneo.2024.100054_bib4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1074-7613(00)80564-6","article-title":"Potent and selective stimulation of memory-phenotype CD8+ T cells in\u00a0vivo by IL-15","volume":"8","author":"Zhang","year":"1998","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bneo.2024.100054_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.bneo.2024.100054_bib6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/cncr.23552","article-title":"High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006","volume":"113","author":"Klapper","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bneo.2024.100054_bib7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40425-017-0279-5","article-title":"High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute","volume":"5","author":"Davar","year":"2017","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"12","key":"10.1016\/j.bneo.2024.100054_bib8","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J\u00a0Immunol"},{"issue":"17","key":"10.1016\/j.bneo.2024.100054_bib9","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1182\/blood-2010-03-275438","article-title":"Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates","volume":"116","author":"Lugli","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2024.100054_bib10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8\u00a0T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2024.100054_bib11","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-17-2451","article-title":"A\u00a0first-in-human phase I study of subcutaneous outpatient recombinant human IL15 (rhIL15) in adults with advanced solid tumors","volume":"24","author":"Miller","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bneo.2024.100054_bib12","doi-asserted-by":"crossref","first-page":"e002193","DOI":"10.1136\/jitc-2020-002193","article-title":"Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies","volume":"9","author":"Dubois","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"16","key":"10.1016\/j.bneo.2024.100054_bib13","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1158\/1078-0432.CCR-18-3468","article-title":"IL15 by continuous intravenous infusion to adult patients with solid tumors in a phase I trial induced dramatic NK-cell subset expansion","volume":"25","author":"Conlon","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"46","key":"10.1016\/j.bneo.2024.100054_bib14","doi-asserted-by":"crossref","first-page":"E10915","DOI":"10.1073\/pnas.1811615115","article-title":"IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages","volume":"115","author":"Zhang","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"43","key":"10.1016\/j.bneo.2024.100054_bib15","doi-asserted-by":"crossref","first-page":"75217","DOI":"10.18632\/oncotarget.20680","article-title":"Analyses of functions of an anti-PD-L1\/TGF\u03b2R2 bispecific fusion protein (M7824)","volume":"8","author":"Jochems","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.bneo.2024.100054_bib16","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/bloodadvances.2021006440","article-title":"Interleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies","volume":"7","author":"Miljkovic","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.bneo.2024.100054_bib17","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1080\/10428194.2024.2326847","article-title":"A\u00a0phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma","author":"Gordon","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.bneo.2024.100054_bib18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/intimm\/11.1.81","article-title":"Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine","volume":"11","author":"Imai","year":"1999","journal-title":"Int Immunol"},{"issue":"22","key":"10.1016\/j.bneo.2024.100054_bib19","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1158\/1078-0432.CCR-04-0983","article-title":"The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia\/lymphoma","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.bneo.2024.100054_bib20","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1046\/j.1523-1747.2002.19610.x","article-title":"Increased CCR4 expression in cutaneous T cell lymphoma","volume":"119","author":"Ferenczi","year":"2002","journal-title":"J\u00a0Invest Dermatol"},{"issue":"5","key":"10.1016\/j.bneo.2024.100054_bib21","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V99.5.1505","article-title":"Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T\u00a0cells","volume":"99","author":"Yoshie","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2024.100054_bib22","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.bneo.2024.100054_bib23","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bneo.2024.100054_bib24","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.bneo.2024.100054_bib25","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.3324\/haematol.2016.146977","article-title":"European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed\/refractory peripheral T-cell lymphoma","volume":"101","author":"Zinzani","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bneo.2024.100054_bib26","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3324\/haematol.2018.205096","article-title":"Mogamulizumab versus investigator\u2019s choice of chemotherapy regimen in relapsed\/refractory adult T-cell leukemia\/lymphoma","volume":"104","author":"Adrienne","year":"2019","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.bneo.2024.100054_bib27","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1182\/bloodadvances.2020003053","article-title":"Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study","volume":"4","author":"Yonekura","year":"2020","journal-title":"Blood Advances"},{"issue":"suppl 16","key":"10.1016\/j.bneo.2024.100054_bib28","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1200\/JCO.2023.41.16_suppl.7504","article-title":"A\u00a0phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for elderly patients with CCR4-positive adult T-cell leukemia\/lymphoma [abstract]","volume":"41","author":"Choi","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.bneo.2024.100054_bib29","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.2021013341","article-title":"Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients","volume":"139","author":"de Masson","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2024.100054_bib30","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1200\/JCO.18.00501","article-title":"Revised adult T-cell leukemia-lymphoma International Consensus Meeting Report","volume":"37","author":"Cook","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.bneo.2024.100054_bib31","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2024.100054_bib32","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.bneo.2024.100054_bib33","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","article-title":"NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy","volume":"6","author":"Wang","year":"2015","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.bneo.2024.100054_bib34","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bneo.2024.100054_bib35","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.14477","article-title":"The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"176","author":"Chihara","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.bneo.2024.100054_bib36","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1182\/bloodadvances.2021005899","article-title":"Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics","volume":"6","author":"Hamadani","year":"2022","journal-title":"Blood Adv"},{"issue":"26","key":"10.1016\/j.bneo.2024.100054_bib37","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.bneo.2024.100054_bib38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.bneo.2024.100054_bib39","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell\u2013engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2024.100054_bib40","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1158\/1078-0432.CCR-08-1254","article-title":"EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies","volume":"15","author":"O'Mahony","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"suppl 8","key":"10.1016\/j.bneo.2024.100054_bib41","article-title":"REDIRECT: a phase 2 study of AFM13 in patients with CD30-positive relapsed or refractory (R\/R) peripheral T cell lymphoma (PTCL) [abstract]","volume":"83","author":"Kim","year":"2023","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.bneo.2024.100054_bib42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"issue":"13","key":"10.1016\/j.bneo.2024.100054_bib43","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood.2023022204","article-title":"Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed\/refractory mature T-cell lymphomas","volume":"143","author":"Hill","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100054_bib44","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1182\/blood-2018-99-110429","volume":"132","author":"d'Amore","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2024.100054_bib45","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.2002.20.1.205","article-title":"Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed","volume":"20","author":"Keating","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2024.100054_bib46","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1080\/10428194.2017.1387908","article-title":"Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas","volume":"59","author":"Roswarski","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.bneo.2024.100054_bib47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","article-title":"Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B\/ACT-2 trial","volume":"35","author":"Wulf","year":"2021","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.bneo.2024.100054_bib48","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood.2023022204","article-title":"Anti-tumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed\/refractory mature T-cell lymphomas","volume":"143","author":"Hill","year":"2024","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.bneo.2024.100054_bib49","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1182\/blood.2021015020","article-title":"Engineering naturally occurring CD7\u2212 T cells for the immunotherapy of hematological malignancies","volume":"140","author":"Freiwan","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100054_bib50","doi-asserted-by":"crossref","first-page":"10316","DOI":"10.1182\/blood-2022-165971","article-title":"First in human study of AUTO4, a TRBC1-targeting CAR T-cell therapy in relapsed\/refractory TRBC1-positive peripheral T-cell lymphoma","volume":"140","author":"Cwynarski","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100054_bib51","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2022-160244","article-title":"CD30.CAR-modified Epstein-Barr virus-specific T cells (CD30.CAR EBVSTs) provide a safe and effective off-the-shelf therapy for patients with CD30-positive lymphoma","volume":"140","author":"Quach","year":"2022","journal-title":"Blood"},{"issue":"S3","key":"10.1016\/j.bneo.2024.100054_bib52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.HS9.0000843940.96598.e2","article-title":"The cobalt-LYM study of CTX130: a phase 1 dose escalation study of CD70 targeted allogeneic CRISPR-CAS9\u2013engineered CAR T cells in patients with relapsed\/refractory (R\/R) T-cell malignancies [abstract]","volume":"6","author":"Iyer","year":"2022","journal-title":"HemaSphere"},{"issue":"10168","key":"10.1016\/j.bneo.2024.100054_bib53","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.bneo.2024.100054_bib54","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician\u2019s choice in cutaneous T-cell lymphoma: final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Advances"},{"issue":"18","key":"10.1016\/j.bneo.2024.100054_bib55","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100054_bib56","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2023-172980","article-title":"Innate cell engager (ICE\u00ae) AFM13 combined with preactivated and expanded (P+E) cord blood (CB)-derived natural killer (NK) cells for patients with refractory CD30-positive lymphomas: final results [abstract]","volume":"142","author":"Nieto","year":"2023","journal-title":"Blood"},{"issue":"8007","key":"10.1016\/j.bneo.2024.100054_bib57","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41586-024-07233-2","article-title":"TRBC1-targeting antibody\u2013drug conjugates for the treatment of T cell cancers","volume":"628","author":"Nichakawade","year":"2024","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.bneo.2024.100054_bib60","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.4049\/jimmunol.177.11.7833","article-title":"Evidence for NK cell subsets based on chemokine receptor expression","volume":"177","author":"Berahovich","year":"2006","journal-title":"J\u00a0Immunol"},{"issue":"11","key":"10.1016\/j.bneo.2024.100054_bib61","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/bloodadvances.2023012202","article-title":"CD70-specific CAR-NK cells expressing IL-15 for the treatment of CD19-negative B cell malignancy","volume":"8","author":"Guo","year":"2024","journal-title":"Blood Advances"},{"issue":"6","key":"10.1016\/j.bneo.2024.100054_bib62","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.bneo.2024.100054_bib58","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1158\/1078-0432.CCR-20-4575","article-title":"Phase I trial of N-803, an IL15 receptor agonist, with rituximab in patients with indolent non-Hodgkin lymphoma","volume":"27","author":"Foltz","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bneo.2024.100054_bib59","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1912885","article-title":"Safety, tolerability, and long-term clinical outcomes of an IL-15 analogue (N-803) admixed with bacillus calmette-gu\u00e9rin (BCG) for the treatment of bladder cancer","volume":"10","author":"Rosser","year":"2021","journal-title":"OncoImmunology"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T02:57:30Z","timestamp":1762657050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328024000542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2950328024000542"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100054","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution.","name":"copyright","label":"Copyright"}],"article-number":"100054"}}